FDA blesses GSK/Theravance COPD drug Anoro Ellipta
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Theravance on 18 December won US approval of Anoro Ellipta, a combination of umeclidinium bromide 62.5mcg, a long-acting muscarinic antagonist (LAMA), and vilanterol 25mcg, a long-acting beta2 agonist (LABA), for the long-term, once-daily maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.